Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-9, canceled.

10. (Currently Amended) A method of treating idiopathic pulmonary fibrosis which comprises <u>orally</u> administering to a patient having idiopathic pulmonary fibrosis a therapeutically effective amount 100-400 mg per day of thalidomide, or a pharmaceutically acceptable salt, or stereoisomer thereof.

11-17. canceled.

- 18. (Currently Amended) The method of claim [16] <u>10</u>, wherein said thalidomide is administered in an amount of 50 mg, 100 mg, 200 mg, 300 mg or 400 mg per day.
- 19. (Currently Amended) The method of claim 10, wherein said thalidomide is in a dosage form for oral, mucosal, potential, topical, transferal or transcutaneous administration to the patient.
- 20. (Currently Amended) The method of claim 19, wherein said dosage form is selected from tablets, caplets, capsules, cachets, troches, lozenges, dispersions, suppositories, powders, aerosols, gels, liquid, eye drops or sterile solids.

21-24. canceled

25. (New) The method of claim 19, wherein said dosage form comprises 100-400 mg of thalidomide and a pharmaceutically acceptable excipient, carrier or diluent.

2

NYI-4198141v1